You are here: Home » Health » News
Business Standard

New study reveals erectile dysfunction drug could treat heart failure too

Heart failure is a devastating condition that occurs when the heart is too weak to pump blood around the body

Andrew Trafford | The Conversation 

Heart, Healthcare
Photo: Shutterstock

In the 1990s, the US drug firm Pfizer was developing drugs to treat angina. During early trials of these drugs, male participants reported a striking side effect: they were getting erections. This discovery led to the development of drugs to treat erectile dysfunction. Our latest study shows that one of these drugs (Cialis) is very effective at treating a particular type of in sheep.

Heart failure is a devastating condition that occurs when the heart is too weak to pump blood around the body. People with heart failure often cannot complete basic tasks without becoming breathless and developing a cough. It is also a condition where survival is worse than for many of the common forms of cancer. The high rates of and the fact that survival is poor highlights the need for newer and more effective treatments for this condition.

In a normal healthy person, the heart pumps more blood around the body when we exercise. This increase in the work performed by the heart is brought about by the hormone adrenaline which makes the heart beat more quickly and pump more strongly. In heart failure, the heart no longer responds properly to adrenaline which means it cannot increase the amount of work it does or pump blood effectively when we exercise.

We discovered that (the generic name for Cialis) was very good at stopping getting worse. It was also surprisingly effective at reversing some changes that had already occurred in the failing heart before the drug was given. In particular, the heart could again respond properly to adrenaline and contract harder. Also, reversed changes that had occurred to the structure of the muscle cells in the heart during the development of heart failure.

The findings from this study, published in Nature, Scientific Reports, may also help explain why people who have been intermittently taking drugs to treat their erectile dysfunction seem to be less likely to have a heart attack or die following a heart attack. Our research adds to the small number of clinical studies that have been performed in patients with heart failure where the related drug sildenafil (Viagra) was reported to improve the patients’ ability to exercise, but the mechanisms behind these positive effects remained elusive.

Cautious optimism

Despite the encouraging results from our study and the fact that drugs to treat are now available without a prescription, we need to remain cautious. The RELAX trial, which reported results in 2013, showed no improvement in exercise capacity in patients receiving sildenafil.

The reason for these differences is probably because two types of heart failure were being investigated in these clinical trials with the positive trials studying patients with systolic heart failure and the neutral trials studying patients with diastolic heart failure. In systolic heart failure, the heart does not contract (pump) adequately whereas in diastolic heart failure the heart still contracts normally but relaxation between heartbeats is impaired.

Still, the experimental findings in our study using and those clinical trials in patients with systolic heart failure offer new hope for an effective treatment for heart failure.

While the work in our study was done using sheep, the strong similarities between the sheep and human hearts in the way they work and respond to disease gives us confidence that these findings will be replicated in humans. Indeed, clinical trials using tadalafil in patients with heart failure are a next step in the process of adding tadalafil to our toolkit to treat patients with heart failure, and we hope to be able to begin these in the near future.


Andrew Trafford, Professor of Cardiac Pathophysiology, University of Manchester

This article is republished from The Conversation under a Creative Commons license. Read the original article.

First Published: Thu, May 02 2019. 12:24 IST